drugset / Trial / NCT02143804

Safety and Efficacy of CG0070 Oncolytic Virus Regimen in Patients With High Grade Non-Muscle Invasive Bladder Cancer

NCT02143804

Phase 2 Withdrawn CG Oncology, Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is an expanded access protocol to study the safety and efficacy of CG0070 in Cis and Cis with Ta and/or T1 disease patients who failed both BCG therapy and the BOND protocol (NCT 01438112), or in high grade Ta and T1 patients who failed BCG therapy.

Timeline

Start
2014-03
Primary completion
2015-03
Completion
2015-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Cretostimogene Grenadenorepvec Unknown 1e+13 vg Other